pembrolizumab,lenvatinib
eisai,merck
['hcc', 'leap-002', 'pembro', 'lenva']
ph3 leap-002 study of lenvatinib+pembrolizumab or placebo as 1l for #ahcc did not meet pre-specified statistical significance! mos 21.2 vs 19.0 mo (hr 0.840, p=0.0227) mpfs 8.2 vs 8.1 mo (hr 0.867, p=0.0466) orr 26.1 vs 17.5% no new aes #livertwitter #esmo22 
Scientific Communication Manager | Passionate about molecular oncology, clinical and translational research | Photo and music enthusiast | Tweets are mine